An anesthesiologist-led inpatient buprenorphine initiative.
Nisarg PatelEric S SchwenkPolina FerdMarc C TorjmanJaime L BarattaEugene R ViscusiPublished in: Pain practice : the official journal of World Institute of Pain (2021)
Hospitalized patients with opioid use disorder who present with acute pain are challenging to manage. Without any treatment, their mortality in the first 28 days after discharge is substantially increased. Unlike extended-release naltrexone, which requires a period of withdrawal, or methadone, which can cause prolonged corrected QT (QTc) and carries a higher risk of respiratory depression, buprenorphine provides potent analgesia with low respiratory risk. Hospitalization provides a unique opportunity for clinicians to perform buprenorphine induction, which could potentially reduce mortality without affecting analgesia. Our acute pain management service uses multimodal analgesia to maintain adequate analgesia and minimize withdrawal during buprenorphine induction in the hospital. With the assistance of narcotics addiction rehabilitation program specialists, we help link patients to outpatient buprenorphine providers and maximize the chance of successful recovery. The primary outcome of this study was to determine the percentage of patients who filled an outpatient buprenorphine prescription after undergoing inpatient induction.
Keyphrases
- pain management
- chronic pain
- mental health
- liver failure
- palliative care
- end stage renal disease
- healthcare
- cardiovascular events
- drug induced
- quality improvement
- respiratory failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- ultrasound guided
- depressive symptoms
- risk factors
- postoperative pain
- type diabetes
- hepatitis b virus
- peritoneal dialysis
- intensive care unit
- aortic dissection
- sleep quality
- physical activity
- adverse drug